-
13975-10A polypharmacological cancer therapeutic potently inhibits RET (IC<sub>50</sub> = 2 nM) and reduces the activity of numerous other kinases by more than 80% when given at 1 &muM in Drosophila interferes with kinases downstream of RET, including
-
13975-5A polypharmacological cancer therapeutic potently inhibits RET (IC<sub>50</sub> = 2 nM) and reduces the activity of numerous other kinases by more than 80% when given at 1 &muM in Drosophila interferes with kinases downstream of RET, including
-
17188-1An inhibitor of ADAMTS-5 (aggrecanase-2 IC<sub>50</sub> = 1.1 µM) with 40-fold selectivity over ADAMTS-4 (aggrecanase-1).
-
17188-5An inhibitor of ADAMTS-5 (aggrecanase-2 IC<sub>50</sub> = 1.1 µM) with 40-fold selectivity over ADAMTS-4 (aggrecanase-1).
-
17188-500An inhibitor of ADAMTS-5 (aggrecanase-2 IC<sub>50</sub> = 1.1 µM) with 40-fold selectivity over ADAMTS-4 (aggrecanase-1).
-
13655-1A selective agonist of retinoic acid receptor (RAR)-&beta and RAR-&gamma (Kds = 34 and 130 nM, respectively) commonly used for the study of the pathogenesis and treatment of acne vulgaris dose-dependently (0.1-10 µM) inhibits sebocyte
-
13655-100A selective agonist of retinoic acid receptor (RAR)-&beta and RAR-&gamma (Kds = 34 and 130 nM, respectively) commonly used for the study of the pathogenesis and treatment of acne vulgaris dose-dependently (0.1-10 µM) inhibits sebocyte
-
13655-250A selective agonist of retinoic acid receptor (RAR)-&beta and RAR-&gamma (Kds = 34 and 130 nM, respectively) commonly used for the study of the pathogenesis and treatment of acne vulgaris dose-dependently (0.1-10 µM) inhibits sebocyte
-
13655-500A selective agonist of retinoic acid receptor (RAR)-&beta and RAR-&gamma (Kds = 34 and 130 nM, respectively) commonly used for the study of the pathogenesis and treatment of acne vulgaris dose-dependently (0.1-10 µM) inhibits sebocyte
-
18650-10An acyclic nucleoside phosphonate that acts as a reverse transcriptase inhibitor demonstrates antiviral activity against herpes viruses, hepatitis B virus, and HIV in animal and clinical models of infections.
-
18650-100An acyclic nucleoside phosphonate that acts as a reverse transcriptase inhibitor demonstrates antiviral activity against herpes viruses, hepatitis B virus, and HIV in animal and clinical models of infections.
-
18650-250An acyclic nucleoside phosphonate that acts as a reverse transcriptase inhibitor demonstrates antiviral activity against herpes viruses, hepatitis B virus, and HIV in animal and clinical models of infections.